Michal Lotem, MD

Trials

Studies that name Michal Lotem, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:32 UTC. Open this list on ClinicalTrials.gov

• Ph1/Ph2
  NCT05296564 · Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

  Hadassah Medical Organization · recruiting · Sarcoma, Synovial, Sarcoma,Soft Tissue, Melanoma Stage IV · principal investigator
• N/A
  NCT04056247 · Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

  OncoHost Ltd. · active not recruiting · Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer · principal investigator
• N/A
  NCT02581228 · Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of Immunotherapy

  Optimata Ltd. · unknown · Melanoma · principal investigator
• Ph1/Ph2
  NCT00279058 · The Role of Peptide-loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2

  Hadassah Medical Organization · completed · Metastatic Melanoma · principal investigator
• Ph1/Ph2
  NCT00278018 · Peritumoral Injection of Immature Dendritic Cells to Irradiated Skin Metastases of Solid Tumors

  Hadassah Medical Organization · terminated · Cancer of Skin, Solid Tumors · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 11:32 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.